PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.…
PolyPid: 3 Key Takeaways for Long-Term Investors
PolyPid (NASDAQ: PYPD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 69 employees.
The shares were at 6.120 USD on 20 November 2026, up 62.8% over 52 weeks. Its 52-week range is 3.500 USD to 7.250 USD: the price is 15.6% below the high and 74.9% above the low.
Its market capitalisation is 129.29M USD.
PolyPid reports return on equity of -311.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 14.24M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 11.50 USD is 87.9% above the current price. The next earnings report is expected on 10 February 2027.